Shares fell 75% to $3.04, putting the stock on track for a record closing low, according to Dow Jones Market Data. The stock ...

BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

Replimune, which was seeking approval of RP1 in combination with Bristol Myers Squibb's Opdivo for the treatment of advanced melanoma, on Tuesday said the FDA issued a so-called complete response ...

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Jim Cramer, a stalwart of stock market commentary, recently shifted gears on Bristol-Myers Squibb, pegging his hopes on their ...

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...